Literature DB >> 15258192

Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein.

Partha Sarathi Biswas1, Kaustuv Banerjee, Mei Zheng, Barry T Rouse.   

Abstract

Herpetic stromal keratitis (HSK) is a T cell-orchestrated, immunoinflammatory lesion that results from corneal Herpes simplex virus infection. Previous reports indicate an essential role for proinflammatory cytokine interleukin (IL)-1 in HSK pathogenesis. The present study evaluates the efficacy of IL-1 receptor antagonist (IL-1 ra) protein in the management of HSK. Mice receiving IL-1 ra had diminished disease severity. The administration of IL-1 ra was shown to reduce the influx into the cornea of cells of the innate and adaptive immune response. In addition, the treatment diminished corneal vascular endothelial growth factor levels, resulting in reduced angiogenic response. Our results show the importance of targeting early proinflammatory molecules such as IL-1 to counteract HSK and advocate IL-1 ra as an effective agent to achieve this.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15258192     DOI: 10.1189/jlb.0504280

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  13 in total

1.  Innate recognition network driving herpes simplex virus-induced corneal immunopathology: role of the toll pathway in early inflammatory events in stromal keratitis.

Authors:  Pranita P Sarangi; Bumseok Kim; Evelyn Kurt-Jones; Barry T Rouse
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

2.  Herpes simplex virus keratitis: histopathology and corneal allograft outcomes.

Authors:  Roni M Shtein; Victor M Elner
Journal:  Expert Rev Ophthalmol       Date:  2010-04-01

Review 3.  Pathogenesis of herpes stromal keratitis--a focus on corneal neovascularization.

Authors:  Fernanda Giménez; Amol Suryawanshi; Barry T Rouse
Journal:  Prog Retin Eye Res       Date:  2012-08-07       Impact factor: 21.198

Review 4.  Corneal lymphangiogenesis in herpetic stromal keratitis.

Authors:  Paul J Park; Michael Chang; Nitin Garg; Jimmy Zhu; Jin-Hong Chang; Deepak Shukla
Journal:  Surv Ophthalmol       Date:  2014-06-10       Impact factor: 6.048

5.  A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes.

Authors:  Aziz A Chentoufi; Gargi Dasgupta; Neil D Christensen; Jiafen Hu; Zareen S Choudhury; Arfan Azeem; James V Jester; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed
Journal:  J Immunol       Date:  2010-02-01       Impact factor: 5.422

6.  Topical interleukin-1 receptor antagonist inhibits inflammatory cell infiltration into the cornea.

Authors:  W Michael Stapleton; Shyam S Chaurasia; Fabricio W Medeiros; Rajiv R Mohan; Sunilima Sinha; Steven E Wilson
Journal:  Exp Eye Res       Date:  2008-02-13       Impact factor: 3.467

7.  Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.

Authors:  Yiping Jin; Makoto Arita; Qiang Zhang; Daniel R Saban; Sunil K Chauhan; Nan Chiang; Charles N Serhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-30       Impact factor: 4.799

8.  Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis).

Authors:  Reza Dana
Journal:  Trans Am Ophthalmol Soc       Date:  2007

9.  Anti-VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis.

Authors:  Mario Saravia; Gustavo Zapata; Paula Ferraiolo; Lourdes Racca; Alejandro Berra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-08-05       Impact factor: 3.117

Review 10.  Novel aspects of corneal angiogenic and lymphangiogenic privilege.

Authors:  David Ellenberg; Dimitri T Azar; Joelle A Hallak; Faisal Tobaigy; Kyu Yeon Han; Sandeep Jain; Zhongjun Zhou; Jin-Hong Chang
Journal:  Prog Retin Eye Res       Date:  2010-01-25       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.